← Back to Clinical Trials
RecruitingNCT06073418

Dietary Habits, Nutritional Knowledge and Physical Activity Assessment in Early Stage Breast Cancer Patients

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionBreast Cancer
SponsorCentro di Riferimento Oncologico - Aviano
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment1,098
SexFEMALE
Min Age18 Years
Max AgeN/A
Start Date2022-10-28
Completion2032-07-01

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The advances in early detection coupled with improvements in treatments have led to an ever increasing number of breast cancer survivors. New methods to improve outcomes, including strategies aimed at improving the quality of life and reducing the risk of other diseases, may complement the currently available treatment options. In particular, interventions targeting diet, weight and physical activity can reduce the risk of cancer occurrence, prevent cancer recurrence, and improve survival and the quality of life.This cross-sectional, prospective, observational study aims at evaluating dietary habits and nutritional knowledge in patients with early hormone receptor positive and hormone receptor negative breast cancer.

Eligibility Criteria

Inclusion Criteria: * Patients with surgically removed early stage (I-IIIa) hormone receptor-positive or hormone receptor negative breast cancer. Patients with hormone receptor-positive breast cancer can be in treatment with endocrine therapy; patients with hormone receptor-negative tumors have to be in follow-up. Concomitant use of targeted therapies with anti-hormonal agents is allowed only in adjuvant setting * Female patients ≥18 years of age. * Written informed consent must be obtained before any study-related assessment is performed Exclusion Criteria: * Patients with advanced/metastatic breast cancer. * Patients with early breast cancer receiving (neo)adjuvant chemotherapy or anti-HER2 agents * Patients receiving active treatment for secondary primary tumors (excluding basal cell carcinoma or in situ neoplasias)

Related Trials